Clinical Characteristics of Multiple Sclerosis in a Cohort of 103 Patients
A retrospective cohort study followed 103 MS patients from 2007 to 2017. Most were women (58.3%), with a median onset age of 38.4 years. The majority presented with RRMS at onset (90.3%) and at the last evaluation (79.6%). Twelve patients (12.9%) progressed to SPMS. Common symptoms at onset were limb weakness (72.8%) and sensory symptoms (72.8%). Initial treatments were mainly interferon-beta (44.7%) and Ocrelizumab (1.9%).
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This study provides insights into the clinical characteristics and treatment patterns of MS patients in Lima, reflecting trends similar to international data. It may help in understanding patient demographics and symptomatic evolution.
What this does not prove
The study does not prove improved disease outcomes and notes that varied treatment strategies could influence results.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 103 · Total number of patients identified
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-08-24
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceClinical and Epidemiological Characteristics of Multiple Sclerosis in a Peruvian Cohort: A Retrospective Study Across Three Lima Hospitals. ↗DOI: 10.3390/neurolint18090160
Supporting passages (8)
study designA descriptive, retrospective cohort study conducted across three major hospitals in Lima.
subjectsWe included adult patients diagnosed with MS in any of its clinical phenotypes-Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS)-who were followed between 2007 and 2017.
sample sizeA total of 103 patients were identified.
sample size basisResults: A total of 103 patients were identified.
publication date2026-08-24
interventionThe most common initial treatment was interferon-beta (44.7%), while two patients (1.9%) initiated therapy with a highly effective disease-modifying drug (DMD), Ocrelizumab.
findingsHowever, we found no evidence of improved disease evolution, a finding potentially attributable to the heterogeneity of treatment and management strategies employed across the cohort.
limitationsThis study describes clinical characteristics at onset and during follow-up that are largely similar to those reported in international series.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.